Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

RICHMOND, CA, USA I April 03, 2025 I Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to ...

Shares of Sangamo Therapeutics Inc (NASDAQ: SGMO) surged 30.2% following the announcement of a significant licensing agreement with pharmaceutical giant Eli Lilly and Company (NYSE: LLY ). The deal ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...